{"id":51614,"date":"2022-12-06T15:02:05","date_gmt":"2022-12-06T14:02:05","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\/"},"modified":"2022-12-06T15:02:05","modified_gmt":"2022-12-06T14:02:05","slug":"level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\/","title":{"rendered":"Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendia\u2019s MammaPrint Low Risk Result Can Safely Forgo Chemotherapy"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>MammaPrint is the only FDA-cleared gene expression test to identify early breast cancer tumors with an Ultra-Low risk that can safely avoid chemotherapy, with a 99% breast cancer specific survival (BCSS) and 97% distant metastasis free interval (DMFI) at 5 years.<\/i>\n<\/li>\n<li>\n<i>Dr. William Audeh, Chief Medical Officer &amp; Breast Medical Oncologist, to present at SABCS 2022 on why current guidelines may to lead unnecessary chemotherapy for many young women with early-stage breast cancer<\/i>\n<\/li>\n<\/ul>\n<p>IRVINE, Calif. &amp; AMSTERDAM&#8211;(BUSINESS WIRE)&#8211;At the 2022 San Antonio Breast Cancer Symposium (SABCS), <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.agendia.com%2F&amp;esheet=53004146&amp;newsitemid=20221206005141&amp;lan=en-US&amp;anchor=Agendia%2C+Inc.&amp;index=1&amp;md5=47b009f8c25c7186d4869e9b7ef0fa77\" rel=\"nofollow noopener\" shape=\"rect\">Agendia, Inc.<\/a>, a leader in breast cancer gene expression profiling, will present data demonstrating its proprietary signatures fulfill a critical unmet need for precise, proactive treatment planning for premenopausal women with early-stage breast cancer. As part of this presentation, Dr. William Audeh, Chief Medical Officer of Agendia, will include new data in the <i>Journal of Clinical Oncology<\/i> that was not available at the time current guidelines were drafted. This data suggests that many young women with early-stage breast cancer may safely avoid the toxicity of chemotherapy if treated appropriately with endocrine therapy.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221206005141\/en\/1655327\/5\/Agendia_Logo_-_600x600.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221206005141\/en\/1655327\/21\/Agendia_Logo_-_600x600.jpg\"><\/a><\/p>\n<p>\n\u201cWhile chemotherapy is certainly necessary for many young women, gene expression profiling with Agendia\u2019s MammaPrint and BluePrint can identify a group of young women with hormone-sensitive cancers who will derive little or no benefit from chemotherapy, and should be offered other options,\u201d said Dr. Audeh. \u201cYoung women have a right to know how much benefit, if any, chemotherapy will provide, so they can make their own decision whether to accept the toxicity of chemotherapy and risk loss of fertility and the serious, and even life-threatening, long-term effects of such therapy.\u201d\n<\/p>\n<p>\nDr. Audeh\u2019s presentation on Thursday, December 8<sup>th<\/sup> at the Exhibitor Product Theater will highlight the following benefits of testing premenopausal women with MammaPrint and BluePrint:\n<\/p>\n<p>\n<b>Identifying premenopausal women with tumors that have a very low risk of metastasizing means avoiding potentially harmful overtreatment with chemotherapy. <\/b>Agendia\u2019s MammaPrint is the only FDA-cleared test that can identify an Ultra-Low risk tumor as a separate risk level from the Low-risk group and therefore inform distinct treatment plans. A recent study published in <i>The Journal of Clinical Oncology, <\/i>from the landmark MINDACT trial<i>, <\/i>found women 50 years old or younger with a MammaPrint Ultra-Low risk result, most of whom did not undergo chemotherapy, had an excellent distant metastasis free survival at 5 years of 97.1% with endocrine therapy alone. [1]. Ultra-Low risk tumors account for 10% to 15% of all breast cancers [2] and represented over 30% of all premenopausal women in the prospective trial [3]. Without the level of precision MammaPrint offers, these tumors\u2019 risk may be underestimated or overtreated.\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Young women deserve the power of choice when weighing small chemotherapy benefit and its impact on their future fertility [5] and quality of life [6]. <\/b>Breast cancer uses estrogen to grow and chemotherapy stops the ovaries\u2019 production of estrogen. While Agendia\u2019s original MINDACT data found a small 3-4% chemotherapy benefit in premenopausal women with a MammaPrint Low risk result, according to a panel of breast cancer experts including Drs. Nadia Harbeck and Reshma Mahatani, it is likely due to this chemotherapy-induced ovarian function suppression (OFS), rather than the effect of chemotherapy itself on the cancer [7]. This means it is possible for women to be spared the irreversible loss of ovarian function that may result from chemotherapy in favor of optimizing OFS and endocrine therapy, without compromising outcomes.\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\n<b>BluePrint accurately identifies aggressive, high-risk tumors that otherwise may be missed<\/b>. BluePrint\u2019s advanced molecular subtyping can spot ER+ Basal Tumors, which can represent up to 29% of ER+ tumors [8]. These tumors are often missed under conventional methods and clinically behave similarity to the highly aggressive triple negative tumors, which disproportionately impact both premenopausal women and Black women [9]. By understanding the underlying genomics driving the growth of one\u2019s unique tumor through molecular subtyping that only Agendia can provide, providers can accurately define each individual tumor and treat with precision.\n<\/li>\n<\/ul>\n<p>\n\u201cPrescribing tests that have this level of precision with women of all ages empowers clinicians with critical insights to precisely treat an individual patient,\u201d said Pat Whitworth, MD, FACS, FSSO, Medical Director, Aptitude Health. \u201cFrom giving young women the option to forgo harsh therapy, to spotting aggressive, yet often-mistaken, tumors early, this information provides women the informed, shared decision-making they deserve. Together, we are changing the way this disease impacts lives, by employing more precise treatments that will put patients on a confident path towards remission or recovery.\u201d\n<\/p>\n<p>\nTo learn more about Agendia\u2019s solutions being showcased at booth #315 at SABCS, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fagendia.com%2Four-tests%2F&amp;esheet=53004146&amp;newsitemid=20221206005141&amp;lan=en-US&amp;anchor=https%3A%2F%2Fagendia.com%2Four-tests%2F&amp;index=2&amp;md5=17bab7891d6f4b61fb6a788d26278c27\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/agendia.com\/our-tests\/<\/a>. Follow Agendia on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FAgendia%3Fref_src%3Dtwsrc%255Egoogle%257Ctwcamp%255Eserp%257Ctwgr%255Eauthor&amp;esheet=53004146&amp;newsitemid=20221206005141&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=518d75244bdda925a7444d5fd779f3ac\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FAgendiaInc%2F&amp;esheet=53004146&amp;newsitemid=20221206005141&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=a189cecee9b4e47f9b1facba837c860a\" rel=\"nofollow noopener\" shape=\"rect\">Facebook<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fagendia-inc-&amp;esheet=53004146&amp;newsitemid=20221206005141&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=0d8fb72083f6662d894be2a4bbbcc22b\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a> for updates throughout the conference.\n<\/p>\n<p>\n<b>About Agendia<\/b>\n<\/p>\n<p>\nAgendia is a mission-driven, commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide. The company currently offers two commercially-available genomic profiling tests that help surgeons, oncologists and pathologists to personalize treatment for women at critical intervention points throughout their patient journey.\n<\/p>\n<p>\nMammaPrint<sup>\u00ae<\/sup> is a 70-gene prognostic test that, along with other clinicopathologic factors, determines a specific patient\u2019s breast cancer recurrence risk. BluePrint<sup>\u00ae<\/sup> is an 80-gene molecular subtyping test that identifies the underlying biology of an individual breast cancer to provide information about its behavior, long-term prognosis and potential response to systemic therapy. Together, MammaPrint<sup>\u00ae<\/sup> and BluePrint<sup>\u00ae<\/sup> provide a holistic view of the biology underlying an individual patient\u2019s breast cancer, enabling physicians to objectively select the best treatment plan.\n<\/p>\n<p>\nFor more information on Agendia\u2019s assays and ongoing trials, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.agendia.com&amp;esheet=53004146&amp;newsitemid=20221206005141&amp;lan=en-US&amp;anchor=www.agendia.com&amp;index=6&amp;md5=941fbacb0d8ed8aa33902517f995c434\" rel=\"nofollow noopener\" shape=\"rect\">www.agendia.com<\/a>.\n<\/p>\n<p>\n<b>References<\/b>\n<\/p>\n<p>\n[1] Cardozo J, Drukker C, et al. Outcomes of patients with an ultralow-risk 70-gene signature in the MINDACT trial. <i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fascopubs.org%2Fdoi%2Fabs%2F10.1200%2FJCO.21.02019&amp;esheet=53004146&amp;newsitemid=20221206005141&amp;lan=en-US&amp;anchor=Journal+of+Clinical+Oncology&amp;index=7&amp;md5=950dc35ff27cff08c4f36c130c54e8a1\" rel=\"nofollow noopener\" shape=\"rect\">Journal of Clinical Oncology<\/a>. <\/i>2022; 40(12): 1335-1345.<br \/>\n<br \/>[2] Esserman LJ, Yau C, et al. Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades. <i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdoi.org%2F10.1001%2Fjamaoncol.2017.1261&amp;esheet=53004146&amp;newsitemid=20221206005141&amp;lan=en-US&amp;anchor=JAMA+Oncol&amp;index=8&amp;md5=6ad7303e9e5acc6bb13b5e83be94c79f\" rel=\"nofollow noopener\" shape=\"rect\">JAMA Oncol<\/a><\/i>. 2017; 3(11):1503-1510.<br \/>\n<br \/>[3] Cardozo J, Drukker C, et al. Outcomes of patients with an ultralow-risk 70-gene signature in the MINDACT trial. <i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fascopubs.org%2Fdoi%2Fabs%2F10.1200%2FJCO.21.02019&amp;esheet=53004146&amp;newsitemid=20221206005141&amp;lan=en-US&amp;anchor=Journal+of+Clinical+Oncology&amp;index=9&amp;md5=825a68ab0759cc70e087b000a0a3444c\" rel=\"nofollow noopener\" shape=\"rect\">Journal of Clinical Oncology<\/a>. <\/i>2022; 40(12): 1335-1345.<br \/>\n<br \/>[4] Sparano J, Gray R. TAILORx: Questions answered, lessons learned, and remaining knowledge gaps. <i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6881095%2F&amp;esheet=53004146&amp;newsitemid=20221206005141&amp;lan=en-US&amp;anchor=Journal+of+Clinical+Oncology&amp;index=10&amp;md5=0b754a24e0317978d6dc88fc68642031\" rel=\"nofollow noopener\" shape=\"rect\">Journal of Clinical Oncology<\/a><\/i>. 2019; 37(21): 1841-1842.<br \/>\n<br \/>[5] Fertility issues in girls and women with cancer. <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cancer.gov%2Fabout-cancer%2Ftreatment%2Fside-effects%2Ffertility-women%23%3A~%3Atext%3DCancer%2520treatments%2520may%2520affect%2520your%2520fertility%26text%3DChemotherapy%2520%2528especially%2520alkylating%2520agents%2529%2520can%2Cand%2520fertility%2520return%2520after%2520treatment&amp;esheet=53004146&amp;newsitemid=20221206005141&amp;lan=en-US&amp;anchor=National+Cancer+Institute&amp;index=11&amp;md5=93e6c755a06a9b198c85e3b7a7b6ea0b\" rel=\"nofollow noopener\" shape=\"rect\">National Cancer Institute<\/a>.<br \/>\n<br \/>[6] Cancer survivors: Late effects of cancer treatment. <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.mayoclinic.org%2Fdiseases-conditions%2Fcancer%2Fin-depth%2Fcancer-survivor%2Fart-20045524&amp;esheet=53004146&amp;newsitemid=20221206005141&amp;lan=en-US&amp;anchor=Mayo+Clinic&amp;index=12&amp;md5=e340f9fe56bf9726c30e4f28720d7742\" rel=\"nofollow noopener\" shape=\"rect\">Mayo Clinic<\/a>.<br \/>\n<br \/>[7] Arboleda B, Bartsch R, et al. Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel. <i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Facademic.oup.com%2Foncolo%2Farticle%2F27%2F9%2F722%2F6608837&amp;esheet=53004146&amp;newsitemid=20221206005141&amp;lan=en-US&amp;anchor=The+Oncologist&amp;index=13&amp;md5=6bc8c99721ee70b2a30c586907fec41c\" rel=\"nofollow noopener\" shape=\"rect\">The Oncologist<\/a>. <\/i>2022; 27(9):722-732.<br \/>\n<br \/>[8] Toft D, Cryns V. Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies. <i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3035993%2F&amp;esheet=53004146&amp;newsitemid=20221206005141&amp;lan=en-US&amp;anchor=Molecular+Endocrinology&amp;index=14&amp;md5=fc75aca8f7a0aa3c1aba6b4e54f88eff\" rel=\"nofollow noopener\" shape=\"rect\">Molecular Endocrinology<\/a><\/i><i>. <\/i>2011; 25(2):199-211.<br \/>\n<br \/>[9] Ibid.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nKerry Harrington<br \/>\n<br \/>FleishmanHillard for Agendia<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;&#58;&#x4b;&#101;&#x72;&#114;&#x79;&#46;&#x68;a&#x72;r&#x69;n&#x67;t&#x6f;n&#64;&#x66;&#108;&#x65;&#105;&#x73;&#104;&#x6d;&#97;&#x6e;&#46;&#x63;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x4b;&#101;&#114;r&#x79;&#x2e;&#104;a&#x72;&#x72;&#105;ng&#x74;&#111;&#110;&#64;&#x66;&#x6c;&#101;i&#x73;&#x68;&#109;&#97;n&#x2e;&#x63;&#111;m<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>MammaPrint is the only FDA-cleared gene expression test to identify early breast cancer tumors with an Ultra-Low risk that can safely avoid chemotherapy, with a 99% breast cancer specific survival (BCSS) and 97% distant metastasis free interval (DMFI) at 5 years. Dr. William Audeh, Chief Medical Officer &amp; Breast Medical Oncologist, to present at SABCS &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51614","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendia\u2019s MammaPrint Low Risk Result Can Safely Forgo Chemotherapy - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendia\u2019s MammaPrint Low Risk Result Can Safely Forgo Chemotherapy - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MammaPrint is the only FDA-cleared gene expression test to identify early breast cancer tumors with an Ultra-Low risk that can safely avoid chemotherapy, with a 99% breast cancer specific survival (BCSS) and 97% distant metastasis free interval (DMFI) at 5 years. Dr. William Audeh, Chief Medical Officer &amp; Breast Medical Oncologist, to present at SABCS ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-06T14:02:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221206005141\/en\/1655327\/21\/Agendia_Logo_-_600x600.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendia\u2019s MammaPrint Low Risk Result Can Safely Forgo Chemotherapy\",\"datePublished\":\"2022-12-06T14:02:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\\\/\"},\"wordCount\":1113,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221206005141\\\/en\\\/1655327\\\/21\\\/Agendia_Logo_-_600x600.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\\\/\",\"name\":\"Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendia\u2019s MammaPrint Low Risk Result Can Safely Forgo Chemotherapy - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221206005141\\\/en\\\/1655327\\\/21\\\/Agendia_Logo_-_600x600.jpg\",\"datePublished\":\"2022-12-06T14:02:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221206005141\\\/en\\\/1655327\\\/21\\\/Agendia_Logo_-_600x600.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221206005141\\\/en\\\/1655327\\\/21\\\/Agendia_Logo_-_600x600.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendia\u2019s MammaPrint Low Risk Result Can Safely Forgo Chemotherapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendia\u2019s MammaPrint Low Risk Result Can Safely Forgo Chemotherapy - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\/","og_locale":"en_US","og_type":"article","og_title":"Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendia\u2019s MammaPrint Low Risk Result Can Safely Forgo Chemotherapy - Pharma Trend","og_description":"MammaPrint is the only FDA-cleared gene expression test to identify early breast cancer tumors with an Ultra-Low risk that can safely avoid chemotherapy, with a 99% breast cancer specific survival (BCSS) and 97% distant metastasis free interval (DMFI) at 5 years. Dr. William Audeh, Chief Medical Officer &amp; Breast Medical Oncologist, to present at SABCS ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-06T14:02:05+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221206005141\/en\/1655327\/21\/Agendia_Logo_-_600x600.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendia\u2019s MammaPrint Low Risk Result Can Safely Forgo Chemotherapy","datePublished":"2022-12-06T14:02:05+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\/"},"wordCount":1113,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221206005141\/en\/1655327\/21\/Agendia_Logo_-_600x600.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\/","url":"https:\/\/pharma-trend.com\/en\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\/","name":"Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendia\u2019s MammaPrint Low Risk Result Can Safely Forgo Chemotherapy - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221206005141\/en\/1655327\/21\/Agendia_Logo_-_600x600.jpg","datePublished":"2022-12-06T14:02:05+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221206005141\/en\/1655327\/21\/Agendia_Logo_-_600x600.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221206005141\/en\/1655327\/21\/Agendia_Logo_-_600x600.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/level-one-evidence-proves-premenopausal-patients-within-the-ultra-low-subset-of-agendias-mammaprint-low-risk-result-can-safely-forgo-chemotherapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendia\u2019s MammaPrint Low Risk Result Can Safely Forgo Chemotherapy"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51614","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51614"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51614\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51614"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51614"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51614"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}